Kezar Life Sciences, Inc. (KZR) NASDAQ
7.29
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Kezar Life Sciences, Inc.
Address
4000 Shoreline Court
South San Francisco, CA 94080
United States of America (the)
Phone
650 822 5600
Sector
Healthcare
Industry
Biotechnology
Employees
55
First IPO Date
June 21, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Christopher J. Kirk | Co-Founder, Chief Executive Officer & Director | 632,000 | 1972 |
| John Franklin Fowler | Co-Founder & Director | 40,000 | 1972 |
| Mark Schiller | Chief Operations Officer | 483,600 | 1980 |
| Marc L. Belsky | Chief Financial Officer & Secretary | 653,208 | 1955 |
| Pichi Chiang | Senior Vice President & Controller | 0 | 1962 |
| Jack Taunton | Co-Founder | 0 | N/A |
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
